GRANULES - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.4
| Stock Code | GRANULES | Market Cap | 14,133 Cr. | Current Price | 582 ₹ | High / Low | 627 ₹ |
| Stock P/E | 36.8 | Book Value | 146 ₹ | Dividend Yield | 0.26 % | ROCE | 10.9 % |
| ROE | 9.14 % | Face Value | 1.00 ₹ | DMA 50 | 577 ₹ | DMA 200 | 553 ₹ |
| Chg in FII Hold | -0.30 % | Chg in DII Hold | 0.60 % | PAT Qtr | 112 Cr. | PAT Prev Qtr | 121 Cr. |
| RSI | 51.9 | MACD | -0.10 | Volume | 17,35,544 | Avg Vol 1Wk | 9,57,403 |
| Low price | 412 ₹ | High price | 627 ₹ | PEG Ratio | -4.28 | Debt to equity | 0.29 |
| 52w Index | 79.1 % | Qtr Profit Var | 23.8 % | EPS | 16.3 ₹ | Industry PE | 27.2 |
📊 Analysis: Granules India (GRANULES) shows weak efficiency with ROCE at 10.9% and ROE at 9.14%, which are below industry standards. The company has moderate leverage (debt-to-equity 0.29), which is manageable. Valuation-wise, the P/E of 36.8 is higher than the industry average of 27.2, suggesting overvaluation. The PEG ratio of -4.28 highlights poor growth prospects relative to price. Dividend yield of 0.26% is negligible. Technical indicators (RSI 51.9, MACD -0.10) show neutral momentum, with the stock trading near DMA 50 (₹577) and above DMA 200 (₹553), suggesting consolidation despite declining quarterly PAT.
💰 Entry Price Zone: Considering valuations and technicals, the ideal entry zone is ₹540–₹560, closer to support levels and below DMA 200. This range offers better risk-reward compared to current levels.
📈 Exit / Holding Strategy: For long-term investors, Granules’ weak ROE/ROCE and negative PEG ratio suggest limited compounding potential. Holding period should be short-to-medium term (1–3 years). Exit strategy should involve profit booking near ₹610–₹620 if valuations expand again. Long-term holding is not recommended unless efficiency metrics improve significantly.
✅ Positive
- Debt-to-equity ratio of 0.29 is manageable.
- DII holdings increased (+0.60%), showing domestic confidence.
- EPS of ₹16.3 reflects steady profitability.
- Stock trading above DMA 200 indicates technical strength.
⚠️ Limitation
- ROE (9.14%) and ROCE (10.9%) are weak compared to peers.
- P/E of 36.8 is higher than industry average (27.2).
- PEG ratio of -4.28 suggests poor growth prospects.
- Dividend yield of 0.26% is negligible.
📉 Company Negative News
- Decline in FII holdings (-0.30%).
- Quarterly PAT dropped from ₹121 Cr. to ₹112 Cr.
📈 Company Positive News
- Quarterly profit variation shows 23.8% growth YoY.
- DII confidence increased (+0.60%).
- EPS of ₹16.3 reflects profitability despite weak efficiency.
🏭 Industry
- Pharmaceutical sector benefits from global demand and healthcare expansion.
- Industry PE of 27.2 reflects moderate optimism in the sector.
📝 Conclusion
Granules India is financially stable but currently overvalued, with weak efficiency metrics and poor growth prospects as reflected in its negative PEG ratio. Ideal entry is around ₹540–₹560. Investors should treat this as a short-to-medium term opportunity (1–3 years), with profit booking near ₹610–₹620 if valuations expand. Long-term holding is not advisable unless ROE/ROCE improve significantly.